ESG-101

N/A

Report date: 2021/11/29 10:56:31

Base Information

Drug NameESG-101

Drug Alias NameESG-101

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized

Mechanisms of ActionUpdating

TargetsUpdating

Therapy Area/IndicationsNerve Degeneration

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesShanghai Escugen Biotechnology Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesShanghai Escugen Biotechnology Co Ltd

Inactive CompaniesN/A

Active IndicationsNerve Degeneration

Inactive IndicationsN/A

Other Information

ATC CodeN/A